Centratherum anthelminticum seeds administration improved risk factor markers in metformin treated type 2 diabetic patients.

This study was designed to assess the effect of Centratherum anthelminticum seeds administration on blood and serum risk factor markers in type 2 diabetic (T2D) patients using metformin. It was a randomized non-blinded, controlled, 3month trial. T2D patients were registered from Sindh Government Hospital New Karachi, Karachi.

Hypoglycemic and hypolipidemic activities of crude seeds of Centratherum anthelminticum in healthy volunteers and type 2 diabetic patients.

This study first time reports the hypoglycaemic activity of crude seeds powder (CSP) of Centratherum anthelminticum in healthy and type 2 diabetic volunteers. In addition, hypolipidemic effect of same CSP was also determined in healthy volunteers. Healthy individuals were divided into control and two test groups T1 and T2 treated with 200 & 400mg of CSP.

Ethanolic seeds extract of Centratherum anthelminticum reduces oxidative stress in type 2 diabetes.

This work was accomplished to assess the in-vitro antiglycation and antioxidant activities of ethanolic seeds extract of Centratherum anthelminticum (CSEt), followed by its in-vivo examination in type 2 diabetes. Overnight fasted rabbits were divided into control and diabetic groups. Rabbits in diabetic group were fed with 35% fructose solution to develop hyperglycemia that was well-monitored by glucometer.